Person: TURAN, ÖMER FARUK
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
TURAN
First Name
ÖMER FARUK
Name
23 results
Search Results
Now showing 1 - 10 of 23
Publication Real world efficacy and safety of teriflunomide in multiple sclerosis: An observational study with four years follow-up(Sage Publications, 2019-09-01) Boz, C.; Terzi, M.; Özakbaş, S.; Yüceyar, N.; Efendi, H.; Balcı, B. P.; Türkoğlu, R.; Karabudak, R.; Soysal, A.; Yetkin, M. F.; Kurne, A.; Akcali, A.; Akman, G.; Demirkiran, M.; Sevim, S.; Kıyıoğlu, N.; Çilingir, V.; Köseoğlu, M.; Uzuner, G.; Ömerhoca, S.; Turan, Ömer Faruk; Kızılay, F.; TURAN, ÖMER FARUK; Tıp Fakültesi; JHM-3244-2023Publication The expression and prognostic value of miR-146a and miR-155 in Turkish patients with multiple sclerosis(Taylor & Francis, 2022-03-04) Sarıdaş, Furkan; Ünlü, Havva Tezcan; Çeçener, Gülşah; Egeli, Ünal; Takanlou, Maryam Sabour; Takanlou, Leila Sabour; Tunca, Berrin; Zarifoğlu, Mehmet; Turan, Ömer Faruk; Taşkapılıoğlu, Özlem; SARIDAŞ, FURKAN; ÇEÇENER, GÜLŞAH; EGELİ, ÜNAL; TUNCA, BERRİN; ZARİFOĞLU, MEHMET; TURAN, ÖMER FARUK; Takanlou, Maryam Sabour; Takanlou, Leila Sabour; Taşkapılıoğlu, Özlem; 0000-0001-5945-2317; 0000-0002-0910-4258; 0000-0002-3820-424X; 0000-0001-7904-883X; 0000-0002-1590-4833; 0000-0002-6361-7150; 0000-0002-1619-6680; HSB-2700-2023; GYU-0252-2022; AAP-9988-2020; AAH-1420-2021; KGL-6846-2024; GRE-6268-2022; ABI-6078-2020; EHN-5825-2022; JDI-6091-2023; EBA-4926-2022Multiple sclerosis (MS) is an inflammatory, autoimmune demyelinating, and neurodegenerative disorder of the central nervous system. Interactions between environmental factors, predisposition genes, and determining genes appear to be involved in its etiology. Epigenetic mechanisms such as microRNA-mediated gene regulation can determine the susceptibility and severity of autoimmune diseases. Therefore, to determine the role of miR-146a and miR-155 in MS and its developmental stages, the expression levels in the serum of MS and clinically isolated syndrome (CIS) patients were compared with those of healthy controls. In the present study, the expression levels of miR-146a and miR-155 were assessed using quantitative Real-Time PCR in blood samples of 15 CIS patients and 61 relapsing-remitting multiple sclerosis (RRMS) patients alongside 32 healthy patients as controls. Furthermore, any associations with the clinicopathologic variables of the patients were also evaluated. Dysregulations were found only in the miR-146a and miR-155 expressions in the RRMS-Control group. When the RRMS patients were evaluated in terms of the characteristics of sex, annual attack rate, age of diagnosis, duration of follow-up, and immunomodulatory treatments used, no significant differences were observed. However, significant dysregulations were identified in miRNA expression in the vitamin D level, EDSS values, and the number of attacks. ROC curve analysis showed that miR-146a and miR-155 were significant in the RRMS-Control group for the area under the curve (AUC). It is possible that miR-146a may be associated with vitamin D deficiency and disease disability, while miR-155 may be associated with the number of attacks.Publication A demographic and polysomnographic investigation of fatigue and sleep disorders in patients with multiple sclerosis(Galenos Yayınevi, 2018-09-01) Sıvacı, Ali Özhan; Demir, Aylin Bican; Turan, Ömer Faruk; Taşkapılıoğlu, Özlem; Bora, İbrahim; Ocakoğlu, Gökhan; Sıvacı, Ali Özhan; BİCAN DEMİR, AYLİN; TURAN, ÖMER FARUK; Taşkapılıoğlu, Özlem; BORA, İBRAHİM HAKKI; OCAKOĞLU, GÖKHAN; Tıp Fakültesi; Biyoistatistik Ana Bilim Dalı; 0000-0002-9697-9510; 0000-0001-6739-8605; 0000-0003-4436-3797; 0000-0002-1114-6051; AAK-6623-2020; V-7170-2017; JCE-6657-2023; AAH-5180-2021; HLG-6346-2023; X-4479-2018Objective: To investigate fatigue and sleep disorders based on demographic, clinical and polysomnographic data and show their effects on the quality of life in multiple sclerosis (MS) patients.Materials and Methods: Thirty MS patients were enrolled in the study depending on the results of the polysomnography (PSG), Fatigue Severity scale, Epworth Sleepiness scale (ESS), Pittsburgh Sleep Quality lindex, Beck Depression and Anxiety inventories. Patients, using (n=16) and non-using (n=14) interferon, were compared with each other in all parameters; ESS and PSG data were compared with a control group consisting of 19 healthy people. Short form-36 (SF-36) data were also compared with the society norms.Results: Central fatigue was observed in 86.7% of the patients. PSG data revealed that stage N2 sleep duration of those who did not use interferon was significantly longer than those who used it (p<0.001). According to the PSG, total sleep time, sleep efficiency, stage N3 and rapid eye movement time, mean respiratory disturbance index, sleep latency and the mean value of total leg movements were significantly higher in the patient group than in the control group (p<0.001). All parameters of SF-36 were significantly lower in patient group (p<0.001). The stage N3 sleep time length was found related with physical component summary of SF-36 (p<0.001).Conclusion: MS patients have high level of fatigue and additionally there are weighty disturbances in objective and subjective sleep parameters. Our findings were revealed that all the components of quality of life decreased significantly in these patients. Furthermore, our study showed that deep sleep duration was related with physical activity and emphasized the importance of sleep evaluation in MS patients.Publication Cladribine responsiveness in switched rrms patients(Sage Publications Ltd, 2023-10-01) Tepe, Nermin; Koç, Emine; Sarıdaş, Furkan; Akkoyun, Fatma; Sarı, Ümmu Serpil; Turan, Ömer Faruk; Kabay, Sibel Canbaz; Tokuçoğlu, Figen; KOÇ, EMİNE RABİA; SARIDAŞ, FURKAN; TURAN, ÖMER FARUK; Tıp Fakültesi; Nöroloji Ana Bilim Dalı; 0000-0001-5945-2317; 0000-0002-6752-1519 ; JAL-2843-2023; HSB-2700-2023; JCO-1811-2023Publication Effects of quarantine applied during the covid-19 pandemic on mental health and quality of life in patients with multiple sclerosis and healthy controls(Springer-verlag Italia Srl, 2022-01-21) Koç, Emine Rabia; KOÇ, EMİNE RABİA; Demir, Aylin Bican; BİCAN DEMİR, AYLİN; Topaloğlu, Ezgi; Turan, Ömer Faruk; TURAN, ÖMER FARUK; Özkaya, Güven; ÖZKAYA, GÜVEN; Tıp Fakültesi; Nöroloji Ana Bilim Dalı; 0000-0002-0264-7284; 0000-0001-6739-8605; A-7083-2015Background The coronavirus outbreak, which emerged in Wuhan, China, in late 2019 and spread to the world, has changed each of our lives. Objective To investigate the effects of quarantine on depression, anxiety, sleep quality, fatigue, and SF-36 of multiple sclerosis (MS) patients during the COVID-19 outbreak and differences between healthy controls (HC). Methods Eighty-six MS patients and 65 HC patients were included in the study. Participants filled out the various scales through face-to-face interviews for mental health assessment from January 15 to February 15, 2021. Results When both groups were compared in terms of BECK-D inventory (p < 0.001), BECK-A inventory (p = 0.010), and FS (p < 0.001), the patient group had significantly higher results. Physical functioning (p < 0.001), physical role limitation (p = 0.001), energy vitality rates (p = 0.010), and general health perception (p < 0.001) were higher in the HC group. When MS patients were divided according to EDSS scores, BECK-A (p < 0.001), BECK-D (p = 0.001), and PSQI (p = 0.006) scores of the patients with EDSS > 3 were higher, while emotional role restriction rates (p = 0.006), energy and vitality (p = 0.018), and pain (p = 0.005) were significantly lower than those with EDSS <= 3. When MS patients were divided into two groups as who had COVID-19 and who did not and compared SF-36 subscale scores, pain, (p = 0.049) and mental status (p = 0.030) were obtained significant differences in the two groups. Conclusions Our study revealed that MS patients, who are more susceptible to the new 'normal' that emerged during the pandemic period, are among the priority groups that should be supported in terms of mental health as well as physical health.Publication Covid-19 infection as a possible risk factor for longitudinally extensive transverse myelitis!(Taylor & Francis Ltd, 2022-07-08) Mengüç, Bedirhan; MENGÜÇ, BEDİRHAN; Koç, Emine Rabia; KOÇ, EMİNE RABİA; Turan, Ömer Faruk; TURAN, ÖMER FARUK; Tıp Fakültesi; Nöroloji Ana Bilim Dalı; 0000-0002-0264-7284; A-7083-2015Introduction There is limited data about the neurological effects of Covid-19 in infected patients. In this report, we present 2 LETM cases that are possibly associated with Covid-19 infection. Methods Here, we present 2 cases that subsequently developed LETM following Covid-19 infection. The first case presented a finding of tetraparesis prominent in the lower extremities that started ten days after the Covid-19 infection. The second patient was admitted with paraparesis and urinary-stool retention on the 12th day from the onset of symptoms of Covid-19 infection. Results In these 2 cases, LETM developing following Covid'19 infection was associated with Covid-19 infection. Although Covid-19 PCR was negative in the CSF of both patients, the Covid-19 PCR test was positive in the samples taken from the oropharynx. Conclusion The mechanism of LETM caused by Covid-19 infection is not clearly known. However, both direct infection of the spinal cord and excessive inflammatory response to primary Covid-19 infection may cause spinal cord damage. Therefore, possible Covid-19-associated myelitis should be kept in mind in cases of long segment transverse myelitis grouped under the title of NMOSD and without any etiological factor.Publication Experience of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis patients(Galenos Yayıncılık, 2012-01-01) Taşkapılıoğlu, Özlem; Turan, Aslı Bahar; Albaş, Murat; Turan, Ömer Faruk; Taşkapılıoğlu, Özlem; Turan, Aslı Bahar; Albaş, Murat; TURAN, ÖMER FARUK; Tıp Fakültesi; Nöroloji Ana Bilim Dalı; 0000-0003-4436-3797; AAK-6623-2020; EEE-2035-2022; EKT-1005-2022; JHM-3244-2023Objective: Glatiramer acetate (GA) has been shown to reduce the number of relapses and improve outcomes in relapsing-remitting multiple sclerosis (RRMS) patients. The aim of this study is to investigate the efficacy and side effects of GA in RRMS patients treated with it.Material and Method: We retrospectively reviewed all the records of RRMS patients treated with GA in our hospital from January 1990 to December 2010. We evaluated 114 records but 71 patients (48 women, 23 men) were included in the study due to incompleteness in the other records. Demographic characteristics, time from first symptom to diagnosis, time from diagnosis to treatment, number of relapses and Expanded Disability Status Scale (EDSS) scores before and after the treatment, treatment duration, side effects, the other agents used in MS treatment during the disease duration and the presence of oligoclonal bands were recorded.Results: The mean age of the patients and mean GA treatment duration were 41.85 +/- 9.05 years and 28.73 months, respectively. The mean number of relapses before and after the treatment were 2.30 +/- 1.16 and 0.52 +/- 1.24 respectively. The number of relapses reduced in 64 (90.14%), unchanged in 4 (5.63%) and increased in 3 (4.23%) patients after GA treatment. The mean EDSS scores before and after the treatment were 2.56 +/- 1.46 and 2.04 +/- 1.68 respectively. Before GA treatment, 63.4% of all patients had EDSS scores three or more. After the treatment 50.6% of all patients had EDSS scores three or more. GA was the first choice immunomodulatory treatment in 71.8% and the second choice in 28.2% of the patients. The treatment discontinued in 8 (11.3%) patients and the reason was the severe side effect in only one patient (1.4%).Discussion: Glatiramer acetate decreased the number of relapses and EDSS score with tolerable side effects.Publication Comparative analysis of fingolimod versus teriflunomide in relapsing-remitting multiple sclerosis(Elsevier Sci Ltd, 2019-11-01) Boz, Cavit; Terzi, Murat; Ozer, Bilge; Türkoğlu, Recai; Karabudak, Rana; Efendi, Hüsnü; Soysal, Aysun; Sevim, Serhan; Altintaş, Ayse; Kurne, Aslı; Akcali, Aylin; Akman, Gülşen; Yüceyar, Nur; Balci, Belgin Petek; Ekmekci, Özgül; Karahan, Serap Zengin; Demirkıran, Meltem; Altunrende, Burcu; Gözübatik Çelik, Gökçen; Kale, Nilüfer; Köseoğlu, Meşrure; Özakbaş, Serkan; Turan, Ömer Faruk; TURAN, ÖMER FARUK; Tıp Fakültesi; JHM-3244-2023Background: Fingolimod and teriflunomide are commonly used in the treatment of relapsing-remitting multiple sclerosis (RRMS). These have not been compared in controlled trials, but only in observational studies, with inconclusive results. Comparison of their effect on relapse and disability in a real-world setting is therefore needed.Objectives: The objective of this study was to compare the efficacy of fingolimod and teriflunomide in reducing disease activity in RRMS.Methods: This multicenter, retrospective observational study was carried out with prospectively collected data from 15 centers. All consecutive RRMS patients treated with teriflunomide or fingolimod were included. Data for relapses, Expanded Disability Status Scale (EDSS) scores and brain magnetic resonance imaging (MRI) scans were collected. Patients were matched using propensity scores.Annualized relapse rates (ARR), disability accumulation, percentage of patients with active MRI and treatment discontinuation over a median 2.5-year follow-up period were compared.Results: Propensity score matching retained 349 out of 1388 patients in the fingolimod group and 349 out 678 in the teriflunomide group for final analyses. Mean ARR decreased markedly from baseline after 1 and 2 years of treatment in both the fingolimod (0.58-0.17 after 1 year and 0.11 after 2 years, p < 0.001) and teriflunomide (0.56-0.29 after 1 year and 0.31 after 2 years, p < 0.001) groups. Mean ARR was lower in fingolimod-treated patients than in those treated with teriflunomide at years 1 (p = 0.02) and 2 (p = 0.004). Compared to teriflunomide, the fingolimod group exhibited a higher percentage of relapse-free patients and a lower percentage of MRI-active patients after 2.5-year follow-up. Disability worsening was similar between the two groups. Patients were less likely to discontinue fingolimod than teriflunomide (p < 0.001).Conclusion: Fingolimod was associated with a better relapse control and lower discontinuation rate than teriflunomide. The two oral therapies exhibited similar effects on disability outcomes.Publication A 12-month, open label, multicenter pilot study evaluating fingolimod treatment in terms of patient satisfaction in relapsing remitting multiple sclerosis patients FINE trial(Aves, 2019-12-01) Akman Demir, Gülşen; Türkoğlu, Recai; Saip, Sabahattin; Yüceyar, Nur; Efendi, Hüsnü; Turan, Ömer Faruk; Ağan, Kadriye; Terzi, Murat; Boz, Cavit; Tuncer, Aslı; Koçer, Belgin; Kasap, Mithat; Çalışkan, Zeynep; FINE Study Grp; TURAN, ÖMER FARUK; Tıp Fakültesi; Nöroloji Ana Bilim Dalı; JHM-3244-2023Introduction: To assess satisfaction and quality of life in patients with relapsing-remitting multiple sclerosis (RRMS) who were receiving fingolimod (0.5 mg/day) for 12 months as a second-line treatment after switching from injectable agents.Methods: Patients aged 18-65 years with RRMS who fulfilled the eligibility criteria were enrolled from 16 centers throughout Turkey. Treatment Satisfaction Questionnaire for Medication and 36-item Short-Form Health Survey were completed at baseline and four visits to assess patient satisfaction and quality of life.Results: Forty-two patients (62% male; mean age: 35.7 +/- 9.4 years) were eligible for inclusion. Patient satisfaction scores at the end of the study 44.7 +/- 9.9) were significantly higher than those at baseline [32.0 +/- 9.9; (p<0.001)]. The only significant increase in the quality of life survey was in the emotional aspect (p=0.019). There were 124 adverse events and none of the five serious adverse events noted was considered drugrelated.Conclusion: Large-scale comparative studies performed with disease specific quality of life instruments will allow more information on this issue.Publication Retrospective analysis of effectiveness of fingolimod in real life setting in Turkey (refine)(Tubitak Scientific & Technological Research Council Turkey, 2023-01-01) Tuncer, Aslı; Kurtuncu, Murat; Terzi, Murat; Uygunoğlu, Ugur; Göncüoğlu, Cansu; Yüceyar, Ayşe Nur; Ekmekçi, Özgül; Türkoğlu, Recai; Soysal, Aysun; Köseoğlu, Mesrure; Boz, Cavit; Beckmann, Yeşim; Demirkiran, Meltem; Akman, Gülsen; Altunrende, Burcu; Cantürk, Ilknur Aydın; Birday, Erkingul; Özcan, Abdulcemal; Kamışlı, Özden; Özen, Nazire Pınar Acar; Çelik, Rabia Gökçen Gözübatik; Balcı, Belgin Petek; Efendi, Hüsnü; Sarıkaya, Cansu; Akçalı, Aylin; Kılınç, Münire; Kabay, Sibel Canbaz; Kızılay, Ferah; Sevim, Serhan; Gazaloğlu, Gülcan Baran; Demir, Caner Feyzi; Balgetir, Ferhat; Kıylıoğlu, Nefati; Sarıahmetoğlu, Hande; Ölmez, Cağcan; Mavi, Kamil; Yüksel, Suha; Işık, Nihal; Saip, Sabahattin; Karabudak, Rana; Siva, Aksel; Eraksoy, Mefkure; Turan, Omer Faruk; TURAN, ÖMER FARUK; Tıp Fakültesi; Nöroloji Ana Bilim Dalı; JHM-3244-2023Background/aim: During multiple sclerosis (MS) treatment different modes of action such as lateral (interferon beta to glatiramer acetate or glatiramer acetate to interferon beta) or vertical (interferon beta/glatiramer acetate to fingolimod) drug switch can be performed. This study aims to investigate the clinical effectiveness of switching from the first-line injectable disease modifying treatments (iDMTs) to fingolimod (FNG) compared to switching between first-line iDMTs.Materials and methods: This is a multicenter, observational and retrospective study of patients with relapsing-remitting MS who had lateral and vertical switch. The observation period included three key assessment time points (before the switch, at switch, and alter the switch). Data were collected from the MS patients' database by neurologists between January 2018 and June 2019. The longest follow-up period of the patients was determined as 24 months after the switch.Results: In 462 MS patients that were included in the study, both treatments significantly decreased the number of relapses during the postswitch 12 months versus preswitch one year while patients in the FNG group experienced significantly fewer relapses compared to iDMT cohort in the postswitch 12 months period. FNG cohort experienced fewer relapses than in the iDMT cohort within the postswitch 2 year. The mean time to first relapse after the switch was significantly longer in the FNG group.Conclusion: The present study revealed superior effectiveness of vertical switch over lateral switch regarding the improvement in relapse outcomes. Patients in the FNG cohort experienced sustainably fewer relapses during the follow-up period after the switch compared the iDMT cohort. Importantly, switching to FNG was more effective in delaying time to first relapse when compared with iDMTs.
- «
- 1 (current)
- 2
- 3
- »